Targeted therapy combined with immunotherapy vs trifluridine/tipiracil with bevacizumab as late-line therapy in metastatic colorectal cancer

Table 1 Demographic and clinical characteristics of the patients at baseline, n (%)

Characteristics	Levels	n
Age	≤ 60	51 (40.2)
	> 60	76 (59.8)
Gender	Male	80 (63.0)
	Female	47 (37.0)
ECOG	0-1	110 (86.6)
	2	17 (13.4)
Primary tumor location	Right colon	31 (24.4)
	Left colon and rectum	96 (75.6)
Primary tumor surgery	No	8 (6.3)
	Yes	119 (93.7)
Number of metastatic organs	1	28 (22.0)
	≥ 2	99 (78.0)
Liver metastasis	No	48 (37.8)
	Yes	79 (62.2)
Lung metastasis	No	47 (37.0)
	Yes	80 (63.0)
RAS	Wild-type	34 (26.8)
	KRAS mutation	62 (48.8)
	NRAS mutation	7 (5.5)
	Unknown	24 (18.9)
Treatment regimen	Targeted drug + PD-1	88 (69.3)
	TAS-102 + bevacizumab	39 (30.7)
BRAF	Wild-type	91 (71.7)
	Mutation	6 (4.7)
	Unknown	30 (23.6)
Prior fluorouracil	No	78 (61.4)
	Yes	49 (38.6)
Prior oxaliplatin	No	19 (15.0)
	Yes	108 (85.0)
Prior irinotecan	No	19 (15.0)
	Yes	108 (85.0)
Prior capecitabine	No	26 (20.5)
	Yes	101 (79.5)
Prior raltitrexed	No	86 (67.7)
	Yes	41 (32.3)
Prior bevacizumab	No	18 (14.2)
	Yes	109 (85.8)
Prior cetuximab	No	95 (74.8)
	Yes	32 (25.2)
Treatment line	3 Line	69 (54.3)
	> 3 Line	58 (45.7)

ECOG: Eastern Cooperative Oncology Group; PD-1: Programmed cell death 1; TAS-102: Trifluridine/tipiracil.